Ikaria to in-license worldwide rights to investigational portofolio from Fibrex Medical
11-Aug-2009 -
Ikaria Holdings, Inc. and Fibrex Medical, Inc. announced that Ikaria has entered into an agreement under which Ikaria has acquired the exclusive worldwide license to Fibrex Medical’s portfolio of investigational compounds for a range of critical care conditions.
The investigational compounds, ...
milestone payments
peptides
pharmacokinetics
+1